REG - OptiBiotix Health - Contract with multinational consumer goods company <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

16/07/2015 08:53

RNS Number : 8554O
OptiBiotix Health PLC
02 June 2015
2 June 2015
OptiBiotix Health plc
("OptiBiotix"orthe Company")
 Contractsigned with multinational consumer goods company
OptiBiotixHealthplc(AIM: OPTI),alifesciencesbusinessdevelopingcompoundstotackleobesity,high
cholesterolanddiabetes, announcesthatithas entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.
The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.
StephenO'Hara,CEOofOptiBiotix,commented:"We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partnersbrand portfolio and global reach will help both companies improve the health and well being of people around the world."
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP
Tel: 020 7148 7900
Liam Murray / Avi Robinson



Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd (Joint Broker)
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Mike Wort
Mob: 07900 608 002
About OptiBiotix Health PLC - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
CNTMMGGVKMNGKZM